Envista Holdings Corp (NVST) Stock Price & Analysis
Envista Holdings Corp (NVST) rose 4.91% to USD 24.59 as of June 10, 2026 at 00:42 UTC, according to Nexqual real-time market data.
NVST last closed at USD 23.44; the session ranged USD 23.69–25.03 on volume of 2,482,902 shares. Market capitalization is $4.00B, with a 52-week range of USD 18.25–30.42 (NYQ). Source: Nexqual, June 10, 2026 at 00:42 UTC.
Key Statistics (as of June 10, 2026 at 00:42 UTC)
| Price | USD 24.59 |
|---|---|
| Change | ▲ 4.91% (up) |
| Previous Close | USD 23.44 |
| Open | USD 23.73 |
| Day Range | USD 23.69 – 25.03 |
| 52-Week Range | USD 18.25 – 30.42 |
| Volume | 2,482,902 shares |
| Market Cap | $4.00B |
| Exchange | NYQ |
Technical Analysis (NVST)
Nexqual's technical model rates NVST "NEUTRAL" based on 3 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 00:42 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.15 (neutral) |
| vs SMA50 | Below (USD 25.13) |
| MACD | -0.47 (negative) |
Analyst Ratings (NVST)
Wall Street analysts rate NVST "None" based on 13 analysts, with a mean price target of USD 29.85 (range USD 21–35), per Nexqual as of June 10, 2026 at 00:42 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 29.85 |
| High Target | USD 35 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 7 / 8 / 0 |
Earnings (NVST)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.33 |
| Revenue Estimate | $715.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.36 vs est 0.31 ▲ beat |
| 2025-12-31 | USD 0.38 vs est 0.32 ▲ beat |
| 2025-09-30 | USD 0.32 vs est 0.28 ▲ beat |
| 2025-06-30 | USD 0.26 vs est 0.23 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financials & Fundamentals (NVST)
| Total Revenue | $2.81B |
|---|---|
| Revenue Growth (YoY) | +14.40% |
| Gross Margin | +55.25% |
| Operating Margin | +9.87% |
| Profit Margin | +2.41% |
| ROE | +2.21% |
| Debt / Equity | 51.61 |
| Current Ratio | 2.44 |
| Total Cash | $1.08B |
| Total Debt | $1.59B |
| Free Cash Flow | $216.34M |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financial Health Score (NVST)
Nexqual rates Envista Holdings Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:42 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 10% |
| Balance Sheet | Strong — $1.08B cash vs $1.59B debt |
| Cash Flow | Solid — FCF $216M, 8% margin |
| Efficiency | Weak — ROE 2%, ROA 3.0% |
Ownership (NVST)
| Insider Ownership | +0.48% |
|---|---|
| Institutional Ownership | +113.35% |
| Shares Outstanding | 162.73M |
| Float | 162.01M |
| Short % of Float | +7.86% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Leadership (NVST)
Envista Holdings Corp is led by Paul A. Keel (age 55), CEO & Director, per Nexqual as of June 10, 2026 at 00:42 UTC.
| CEO & Director | Paul A. Keel (age 55) |
|---|---|
| Senior VP & CFO | Eric D. Hammes (age 50) |
| Senior VP & President of Diagnostics | Robert Befidi (age 50) |
| Senior VP & President of Orthodontics | Veronica Acurio (age 54) |
| Vice President of Investor Relations | Jim Gustafson |
Major Backers & Investors (NVST)
Notable institutional backers of Envista Holdings Corp include Ariel Investments, LLC, Morgan Stanley, Franklin Resources, Inc., according to Nexqual as of June 10, 2026 at 00:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ariel Investments, LLC | 6.68% |
| Morgan Stanley | 5.4% |
| Franklin Resources, Inc. | 4.24% |
| Gates Capital Management, Inc. | 3.3% |
| Alliancebernstein L.P. | 3.09% |
| Franklin Value Investors Trust-FRANKLIN SMALL CAP VALUE FUND | 2.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.25% |
| BlackRock | 14.37% |
| Dimensional Fund Advisors | 6.01% |
| State Street | 3.21% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
From Envista Holdings Corp's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally.
- The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
- The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products.
- This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| EHC | Encompass Health Corporation | USD 104.19 | ▲ 0.17% |
| OPCH | Option Care Health, Inc. | USD 21.11 | ▲ 2.93% |
| ITGR | Integer Holdings Corporation | USD 94.1 | ▲ 2.3% |
| SHC | Sotera Health Company | USD 16.53 | ▲ 5.83% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:42 UTC. This page is informational and not investment advice.